Endocrine Abstracts

The aim of the study was to assess the effectiveness of postmenopausal osteoporosis (PMOP) therapy with denosumab.Patients and methods 32 postmenopausal women with established PMOP for a period of 24 months or more received denosumab 60 mg subcutaneously once every 6 months combined with calcium and vitamin D. A quantitative assessment of bone mineral density (BMD) was carried out before treatment, after 12 and 24 months of observation, using dual-energy X-ray absorptiometry of the lumbar spine (LI – IV) and femoral neck (FN) on the right and left. Changes in the severity of pain were assessed using a visual analogue scale (VAS), the severity of the pain syndrome was assessed before treatment, after 12 and 24 months of observation.Statistical processing was carried out using the SPSS 23.0 software package.

Results and Discussion: The average age of women included into the study was 61.76 (59.35; 68.47) years. The average age at the onset of menopause was 47.52 (43.13; 49.83) years, the average duration of menopause at the time of the study was 12.64 (10.10; 21.62) years.The median values of the T-score in LI-IV before, after 12 and 24 months of treatment were, respectively: «-»2,5/«-»2.1/«-»1.85 (P<0,0001).The median values of the T-score in the FN on the right before and after 12 months of treatment were “-”1.9/”-”1.7 (P=0.07); The median values of the T-score in the FN on the left before and after 12 months of treatment were “-”1.9/”-”1.5 (P=0.04).The median values of the T-score in the FN on the right before and after 24 months of treatment were “-”1.9/”-”1.5 (P=0.012); The median values of the T-score in the FN on the left before and after 24 months of treatment were “-”1.9/”-”1.4 (P=0.01).The median values of pain severity according to VAS before, after 12 and 24 months of treatment were 5.5/4/2 points, respectively (P<0.0001).After 24 months of using denosumab, the mineralization indices of all the studied localizations significantly improved in comparison with the initial data.

Conclusions: Therapy with denosumab 60 mg subcutaneously 2 times a year with an interval of 6 months for 24 months in combination with calcium and vitamin D made it possible to significantly increase the BMD of the lumbar spine and significantly reduce the severity of pain syndrome according to VAS.